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Rifabutin-associated uveitis has been recognized as a dosage-dependent side effect. Previous studies
have reported that clarithromycin or ﬂuconazole may elevate concentrations of rifabutin through inhi-
bition of metabolism through the cytochrome P-450 pathway. Nelﬁnavir is a protease inhibitor widely
used in the treatment of human immunodeﬁciency virus (HIV) infection. The interactions between
protease inhibitors and rifabutin have not been reported in clinical practice. Therefore, we present a case
of bilateral uveitis associated with coadministration of rifabutin and nelﬁnavir. Uveitis did not subside
until discontinuation of rifabutin. To our knowledge, this is the ﬁrst report of uveitis with concurrent
administration of rifabutin and nelﬁnavir. Our ﬁnding reminds us that rifabutin dosage should be
reduced when it is administered with protease inhibitors.
Copyright © 2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Rifabutin-associated uveitis has been reported in both immu-
nosuppressed and immunocompetent individuals, and is recog-
nized as a dosage-dependent side effect.1,2 Previous reports have
mentioned that concurrent administration of rifabutin and clari-
thromycin or ﬂuconazole will increase concentrations of rifabutin
through inhibition of the cytochrome P-450 (CYP450) system, and
an accompanying increase in the incidence of rifabutin toxicities,
including uveitis. Here, we report a case of uveitis associated with
coadministration of rifabutin and nelﬁnavir. Neither clarithromycin
nor ﬂuconazole was given during this period.
2. Case report
A 40-year-old human immunodeﬁciency virus (HIV)-infected
man who received lamivudine/zidovudine coformulation and nel-
ﬁnavir (1250 mg twice daily) regularly, suffered from eye pain andal or nonﬁnancial conﬂicts of
mology, Kaohsiung Medical
umber 100, Tzyou 1st Road,
ciety of Taiwan. Published by Elsevblurred vision in his left eye 93 days after receiving rifabutin
(300mg/day),methaniazide (500mg/day), pyrazinamide (1500mg/
day), and ethambutol (800 mg/day) for pulmonary tuberculosis. He
visited the municipal hospital, and left-eye panuveitis was noted.
According to the patient’s statement, anterior chamber inﬂamma-
tion improved after administration of topical steroids (0.1% dexa-
methasone Q3H) and cycloplegics (1% atropine TID) without
discontinuation of the antituberculosis drug. However, uveitis in the
left eye deteriorated while tapering topical steroids. Right-eye
panuveitis occurred after rifabutin was given for 111 days. The pa-
tient was transferred to our hospital for further management.
Fibrin and hypopyon in the anterior chamber, and vitreous haze
were revealed in the ocular examination (Figs. 1 and 2). Rifabutin-
associated uveitis was suspected on the basis of the course of dis-
ease and clinical presentation. Following discontinuation of rifa-
butin with administration of topical steroids and cycloplegics,
bilateral uveitis resolved (Fig. 3). His visual acuity also recovered
from hand motion to 20/20.
3. Discussion
In HIV-positive patients, many conditions may be associated
with uveitis, including neoplasms, opportunistic infection, inﬂam-
mation due to HIV infection itself, and drug toxicities.3 Our casewas
negative for HLA-B27 and syphilis. Intraocular inﬂammationier Taiwan LLC. All rights reserved.
Fig. 1. Slit-lamp photograph showing severe cell reaction, ﬁbrin, and a hypopyon in
the anterior chamber.
Fig. 2. Fundus photograph showing vitreous haze in the right eye of the patient after
receiving rifabutin for 111 days.
Fig. 3. Fundus photograph showing that the vitreous became clearer 4 days after
discontinuation of rifabutin.
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recurrence.
Previous studies reported that rifabutin-associated uveitis may
develop after 2 weeks to 9 months of treatment.4 The most
frequent type is unilateral anterior uveitis with concomitant mild
vitritis, but bilateral cases, intermediate uveitis, panuveitis, or even
dense vitritis mimicking infectious endophthalmitis or panoph-
thalmitis have also been reported.4e6 However, it often resolved
within 1e2 months after drug discontinuation and the use of
intensive topical corticosteroids and cycloplegics.4,7,8
Rifabutin-associated uveitis has been identiﬁed as a dosage-
dependent side effect, and adverse effects are uncommon at the
recommended dose of 300 mg/day.9 Our patient did not receive
clarithromycin or ﬂuconazole, which might raise the serum con-
centration of rifabutin through inhibition of the CYP450 system.10
The interactions between protease inhibitors (PIs) and rifabutin
have been documented recently. PIs are metabolized by the CYP450
system. Coadministration of PIs and rifabutin will reduce the
clearance of rifabutin11 and increase the incidence of rifabutin tox-
icities, including uveitis.12 Nelﬁnavir, a PI, ismetabolized bymultiple
CYP enzymes, including CYP3A and CYP2C19. Coadministration of
rifabutin with nelﬁnavir may increase the area under the concen-
trationetime curve of rifabutin to 207%, compared with adminis-
tration of rifabutin alone.13 Therefore, dosage reduction of rifabutin
to one-half theusual dose is recommendedwhenadministeredwith
nelﬁnavir, whose preferred dose is 1250 mg BID.13
To our knowledge, this is the ﬁrst report of uveitis with con-
current administration of rifabutin and nelﬁnavir when the rifa-
butin dosage was not reduced according to recommendations.13
This ﬁnding indicates that rifabutin dosage should be reduced
when it is administered with nelﬁnavir. In this type of uveitis
condition, in addition to topical steroid use, rifabutin discontinua-
tion is needed.
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